Abraxane

(Nab-paclitaxel)

ApprovedSmall molecule

Nab-paclitaxel is a cancer medication used to treat several types of cancer including breast cancer, lung cancer, and pancreatic cancer by stopping cancer cells from dividing and growing.[2] Abraxane is currently approved and in use across 89 indications[4].[1]

Abraxane is one of 1121 small molecule programs targeting Pancreatic Cancer. It is currently in Approved.

Indications

633

Total Trials

Active Trials

1,120

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Pancreatic CancerTerminated

Lung CancerCompleted

Esophageal CancerCompleted

AdenocarcinomaUnknown status

Triple-Negative Breast CancerCompleted

Pancreatic Ductal AdenocarcinomaTerminated

Head and Neck Squamous Cell CarcinomaActive, not recruiting

CancerTerminated

ChemotherapyRecruiting

Neoadjuvant ImmunotherapyActive, not recruiting

Pancreatic CancerPhase 3

Terminated

Lung CancerPhase 3

Completed

Esophageal CancerPhase 2

Completed

AdenocarcinomaPhase 2

Unknown status

Triple-Negative Breast CancerPhase 3

Completed

Pancreatic Ductal AdenocarcinomaPhase 3

Terminated

Head and Neck Squamous Cell CarcinomaPhase 2

Active, not recruiting

CancerPhase 1

Terminated

ChemotherapyPhase 2

Recruiting

Neoadjuvant ImmunotherapyPhase 2

Active, not recruiting

Showing 10 of 89 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Abraxane

Bristol-Myers Squibb

Approved

87 2

Zolymbus

AbbVie

Preclinical

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

Nubain

AAultman Health Foundation

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 9

Ablavar

LLantheus Medical Imaging

Preclinical

2 10

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/AActive, not recruiting

Pancreatic Adenocarcinoma

NCT02921022

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT04956692

Phase 1/2Active, not recruiting

First Line Therapy

NCT05918133

Phase 3Recruiting

Nausea and Vomiting

NCT06017284

Phase 2Not yet recruiting

Squamous Cell Carcinoma

NCT06016413

Phase 2Recruiting

Pancreatic Cancer

NCT06423326

Clinical

Trials by Indication[1]

Pancreatic Cancer51 trials

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer

Active, not recruiting·GGeorgetown University·Phase 2·NCT05827055·30 enrolled

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Not yet recruiting·FFudan University·Phase 1/2·NCT06370754·117 enrolled

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Completed·LLokon Pharma AB·Phase 1/2·NCT02705196·51 enrolled

Show 48 more trials

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Active, not recruiting·FFlemming Forsberg·Phase 1/2·NCT04821284·120 enrolled

A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT06532331·87 enrolled

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Recruiting·EEmory University·Phase 2·NCT06423326·36 enrolled

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Completed·EEmory University·Phase 2·NCT03910387·23 enrolled

QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer

Terminated·PPrecision Biologics, Inc·Phase 1/2·NCT01834235·81 enrolled

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Completed·PPanbela Therapeutics, Inc.·Phase 1·NCT03412799·50 enrolled

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Active, not recruiting·AAgenus Inc.·Phase 2·NCT05630183·81 enrolled

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02138383·25 enrolled

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02394535·25 enrolled

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT02231723·139 enrolled

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

Unknown status·—·Phase 1·NCT03703063·30 enrolled

Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer

Completed·WWashington University School of Medicine·Phase 1·NCT02283372·30 enrolled

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

Completed·TTheriva Biologics SL·Phase 2·NCT05673811·112 enrolled

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients

Terminated· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT01461915·60 enrolled

Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer

Active, not recruiting·FFudan University·Phase 3·NCT06018883·100 enrolled

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02930902·9 enrolled

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Completed·—·Phase 1·NCT04634539·18 enrolled

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Recruiting·NNYU Langone Health·Phase 1·NCT05984602·10 enrolled

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Completed·EEmory University·Phase 2·NCT04524702·10 enrolled

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Terminated· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT01632306·13 enrolled

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Not yet recruiting·SShanghai YingLi Pharmaceutical Co. Ltd.·Phase 1/2·NCT06662669·120 enrolled

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

Recruiting·LLoma Linda University·Phase 2·NCT03492671·30 enrolled

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Active, not recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT04539808·42 enrolled

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT03649321·9 enrolled

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Withdrawn·PPiedmont Cancer Institute·Phase 1/2·NCT03797443

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

Recruiting·EEngeneic Pty Limited·Phase 1/2·NCT07049055·144 enrolled

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Completed·NNewLink Genetics Corporation·Phase 1/2·NCT02077881·157 enrolled

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03329248·6 enrolled

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT03535727·48 enrolled

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Completed·KKyntra Bio·Phase 1/2·NCT02210559·37 enrolled

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03586869·3 enrolled

Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

Completed·GGWT-TUD GmbH·Phase 1/2·NCT04257448·75 enrolled

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Unknown status·—·Phase 1/2·NCT03989310·50 enrolled

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Completed·PPancreatic Cancer Research Team·Phase 1/2·NCT01488552·60 enrolled

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT06051851·177 enrolled

A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer

Completed·OOsaka Medical Center for Cancer and Cardiovascular Diseases·Phase 1·NCT02272738·54 enrolled

Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer

Unknown status·UUS Oncology Research·Phase 1·NCT01934634·24 enrolled

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

Recruiting·FFudan University·Phase 2·NCT06196788·30 enrolled

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Terminated·—·Phase 1·NCT03520790·36 enrolled

Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02017015·83 enrolled

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06360354·350 enrolled

Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

Unknown status·FFudan University·Phase 3·NCT04835064·600 enrolled

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Completed·HHalozyme Therapeutics·Phase 2·NCT01839487·279 enrolled

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT05562297·50 enrolled

Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer

Recruiting·EEBG MedAustron GmbH·N/A·NCT04894643·10 enrolled

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03336216·205 enrolled

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Unknown status·—·Phase 1/2·NCT05327582·65 enrolled

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01964430·866 enrolled

Breast Cancer34 trials

A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer

Completed·UUniversity of Utah·Phase 1/2·NCT00748553·30 enrolled

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04335006·80 enrolled

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Recruiting·HHenan Cancer Hospital·Phase 3·NCT07057427·812 enrolled

Show 31 more trials

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04132817·12 enrolled

Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

Terminated·—·Phase 2·NCT02598310·30 enrolled

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Withdrawn·MMayo Clinic·Phase 1·NCT04249167

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Completed·—·Phase 1·NCT02999477·32 enrolled

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

Completed·JJapan Breast Cancer Research Group·Phase 3·NCT02514681·226 enrolled

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Not yet recruiting·EEmory University·Phase 2·NCT06492759·29 enrolled

Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer

Unknown status·SShanghai Cancer Hospital, China·Phase 2·NCT01625429·30 enrolled

Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT01565499·83 enrolled

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)

Completed·GGBG Forschungs GmbH·Phase 3·NCT01583426·1,229 enrolled

Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

Unknown status·—·Phase 2·NCT04498793·55 enrolled

PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03166085·12 enrolled

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1·NCT06121570·24 enrolled

Neoadjuvant Treatment of Breast Cancer

Completed·UUniversity of California, Irvine·Phase 2·NCT00254592·43 enrolled

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Unknown status·SShandong Cancer Hospital and Institute·Phase 2·NCT04676997·20 enrolled

Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06802757·72 enrolled

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Recruiting·FFudan University·Phase 2·NCT06387628·74 enrolled

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03387085·9 enrolled

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Completed·PPriyanka Sharma·Phase 1/2·NCT02379247·43 enrolled

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Unknown status·FFudan University·Phase 2·NCT04355858·319 enrolled

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05981001·170 enrolled

POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer

Withdrawn·MMedSIR·Phase 1/2·NCT04826016

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00675259·33 enrolled

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05840211·654 enrolled

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 2·NCT02685059·174 enrolled

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Unknown status·FFudan University·Phase 2·NCT04734262·98 enrolled

A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT02019277·50 enrolled

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07340398·200 enrolled

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Active, not recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT04398914·216 enrolled

A Study for the Neoadjuvant Treatment of Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05420454·1,576 enrolled

EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT Cancer

Completed·FFondazione Sandro Pitigliani·Phase 2·NCT02783222·160 enrolled

Non-Small Cell Lung Cancer11 trials

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04623775·468 enrolled

Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer

Completed·—·Phase 1/2·NCT02733250·10 enrolled

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Terminated·EEQRx International, Inc.·Phase 3·NCT05493501·8 enrolled

Show 8 more trials

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04956692·531 enrolled

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT02367781·723 enrolled

Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer

Terminated·YYale University·Phase 2·NCT02590003·3 enrolled

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169738

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Completed· Roche logo

Roche·Phase 3·NCT03456063·453 enrolled

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02775435·559 enrolled

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02574078·341 enrolled

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Terminated·AAlliance Foundation Trials, LLC.·Phase 2·NCT02967133·7 enrolled

Pancreatic Adenocarcinoma11 trials

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

Recruiting·—·Phase 2·NCT05241249·37 enrolled

Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma

Unknown status·SSun Yat-sen University··NCT04365049·100 enrolled

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma

Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 1/2·NCT02504333·168 enrolled

Show 8 more trials

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Terminated·AAravive, Inc.·Phase 1/2·NCT04983407·34 enrolled

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT02921022·110 enrolled

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT02993731·1,134 enrolled

Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

Not yet recruiting·NNorthwell Health·Phase 1·NCT07253662·10 enrolled

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

Completed·IIRCCS San Raffaele·Phase 1/2·NCT01730222·137 enrolled

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Unknown status·CCSPC Ouyi Pharmaceutical Co., Ltd.·Phase 2·NCT05047991·153 enrolled

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Completed·PPharmacyclics LLC.·Phase 3·NCT02436668·430 enrolled

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Recruiting·MMedical University of South Carolina·Phase 2·NCT07076212·52 enrolled

Pancreatic Ductal Adenocarcinoma9 trials

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Completed·WWashington University School of Medicine·Phase 1/2·NCT03496662·40 enrolled

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Completed· Novartis logo

Novartis·Phase 3·NCT04935359·511 enrolled

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting·AAustralasian Gastro-Intestinal Trials Group·Phase 2·NCT05042128·158 enrolled

Show 6 more trials

Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Completed·SSamsung Medical Center·Phase 2·NCT02426281·111 enrolled

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Terminated·—·Phase 3·NCT02101021·25 enrolled

Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma

Withdrawn·GGeorgetown University·Phase 1·NCT06017323

PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

Terminated·AAndrew Ko·Phase 2·NCT02487277·3 enrolled

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Terminated·GGerman Cancer Research Center·Phase 1·NCT05494866·6 enrolled

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruiting·WWashington University School of Medicine·Phase 1/2·NCT06904378·61 enrolled

55 more indications

Triple-Negative Breast Cancer7 trials

A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer

Completed·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1/2·NCT03872791·52 enrolled

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Recruiting·AAkeso·Phase 3·NCT06767527·416 enrolled

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Terminated· Gilead logo

Gilead·Phase 2·NCT04958785·92 enrolled

Show 4 more trials

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Terminated· Roche logo

Roche·Phase 2·NCT02322814·169 enrolled

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT04085276·531 enrolled

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Unknown status·IInfinity Pharmaceuticals, Inc.·Phase 2·NCT03961698·91 enrolled

To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05491694·20 enrolled

Nab-paclitaxel6 trials

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Unknown status·FFudan University·Phase 2·NCT05174832·136 enrolled

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Completed· GSK logo

GSK·Phase 1·NCT01192165·169 enrolled

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT02392507·54 enrolled

Show 3 more trials

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT06483555·104 enrolled

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

Completed·—·Phase 2·NCT02716038·39 enrolled

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Terminated·NNisha Mohindra, MD·Phase 1/2·NCT02382406·46 enrolled

Chemotherapy4 trials

CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)

Recruiting·JJohn Lenehan·Phase 1·NCT06393400·20 enrolled

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Completed·LLaekna Limited·Phase 1/2·NCT05383482·22 enrolled

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT03611556·213 enrolled

Show 1 more trial

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Recruiting·AAHS Cancer Control Alberta·Phase 2·NCT05451043·62 enrolled

Squamous Cell Carcinoma3 trials

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01412229·40 enrolled

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03387111·4 enrolled

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06016413·30 enrolled

Advanced Solid Tumors3 trials

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03184870·332 enrolled

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Completed·EEucure (Beijing) Biopharma Co., Ltd·Phase 1/2·NCT04481009·26 enrolled

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03396445·182 enrolled

Lung Cancer2 trials

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03421353·76 enrolled

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Recruiting·VVanderbilt-Ingram Cancer Center·Phase 1/2·NCT05501665·25 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

Completed·SSun Yat-Sen University Cancer Center·Phase 2·NCT04548440·50 enrolled

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Terminated· Novartis logo

Novartis·Phase 3·NCT03631199·673 enrolled

Gastric Cancer2 trials

IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer

Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 1/2·NCT07361991·50 enrolled

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Not yet recruiting·FFujian Medical University·Phase 2·NCT05524974·203 enrolled

Urothelial Carcinoma2 trials

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Terminated·SSCRI Development Innovations, LLC·Phase 2·NCT02887248·3 enrolled

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Active, not recruiting· Roche logo

Roche·Phase 1·NCT05867121·102 enrolled

Refractory Solid Tumors2 trials

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01962103·107 enrolled

Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

Completed·EEmory University·Phase 1·NCT03507491·24 enrolled

Neoadjuvant Chemotherapy2 trials

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06837948·160 enrolled

Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC

Completed·WWest China Hospital·Phase 2·NCT05516589·40 enrolled

Advanced Malignancies2 trials

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1·NCT01929941·5 enrolled

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1/2·NCT02265510·83 enrolled

Metastatic2 trials

Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02732938·22 enrolled

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

Completed·PPancreatic Cancer Research Team·Phase 1/2·NCT01893801·25 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169764

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Unknown status·XXiang Lu·Phase 2·NCT06235918·30 enrolled

Immunotherapy2 trials

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06300424·32 enrolled

Second-line Immunotherapy for ES-SCLC

Recruiting·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT06853678·30 enrolled

First Line Therapy2 trials

First-line Therapy in Metastatic PDAC

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2·NCT03487016·270 enrolled

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Active, not recruiting·BBiotheus Inc.·Phase 1/2·NCT05918133·42 enrolled

Locally Advanced Head and Neck Cancer1 trial

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer

Completed·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT00851877·37 enrolled

Colorectal Cancer1 trial

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03563157·2 enrolled

Recurrent or Metastatic1 trial

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Suspended· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT03777579·375 enrolled

Head and Neck Cancer1 trial

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

Completed·UUniversity of Chicago·Phase 2·NCT03107182·72 enrolled

Radiotherapy1 trial

Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression

Terminated·WWashington University School of Medicine·Phase 2·NCT03655080·2 enrolled

Patients With Advanced Solid Tumors1 trial

Study of DF1001 in Patients With Advanced Solid Tumors

Completed·DDragonfly Therapeutics·Phase 1/2·NCT04143711·270 enrolled

Urothelial Cancer1 trial

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03197571

Ovarian Cancer1 trial

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed·EEpicentRx, Inc.·Phase 2·NCT02489903·139 enrolled

ESS1 trial

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT04299880·7 enrolled

Desmoplastic Small Round Cell Tumor1 trial

Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma

Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 2·NCT03275818·69 enrolled

Metastatic Melanoma1 trial

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00833807·30 enrolled

Melanoma1 trial

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Completed·MMayo Clinic·Phase 1·NCT02020707·43 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT01633970·240 enrolled

Esophageal Carcinoma1 trial

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT05173246·43 enrolled

Adenocarcinoma1 trial

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT05687357·140 enrolled

Concurrent Chemoradiotherapy1 trial

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC

Unknown status·FFuzhou General Hospital·Phase 2·NCT04015661·92 enrolled

Adult Subject1 trial

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06917079·387 enrolled

Nausea and vomiting1 trial

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Recruiting·FFudan University·Phase 3·NCT06017284·100 enrolled

Nasopharyngeal Carcinoma1 trial

Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 1·NCT06611150·24 enrolled

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03345810·200 enrolled

Non-squamous NSCLC1 trial

Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.

Withdrawn·WWest Virginia University·Phase 2·NCT02405910

Locally Advanced1 trial

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Unknown status·OOncoSec Medical Incorporated·Phase 2·NCT03567720·65 enrolled

Locally Advanced or Metastatic NSCLC1 trial

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

Withdrawn· Novartis logo

Novartis·Phase 3·NCT05791097

PD-L1 Positive1 trial

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Withdrawn·UUniversity of Colorado, Denver·Phase 2·NCT05233696

Hyperbilirubinemia1 trial

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02267707·1 enrolled

Esophageal Cancer1 trial

Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)

Recruiting·SShanghai Zhongshan Hospital·Phase 1·NCT07317609·60 enrolled

Malignant Tumors1 trial

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

Completed·CCantargia AB·Phase 1/2·NCT03267316·167 enrolled

Merkel Cell Carcinoma1 trial

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03167164

Soft Tissue Sarcoma1 trial

NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma

Terminated·SSwiss Cancer Institute·Phase 1/2·NCT03524898·39 enrolled

Locally Advanced/Metastatic Solid Tumors1 trial

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Recruiting·—·Phase 1/2·NCT05699811·40 enrolled

Unresectable Cancer1 trial

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated·IImmodulon Therapeutics Ltd·Phase 1/2·NCT03009058·2 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Withdrawn·EEmory University·Phase 2·NCT05514912

Cancer1 trial

Safety Study of SEA-CD40 in Cancer Patients

Terminated· Pfizer logo

Pfizer·Phase 1·NCT02376699·159 enrolled

Radiation Therapy1 trial

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

Terminated·VVanderbilt-Ingram Cancer Center·Phase 1/2·NCT00544648·13 enrolled

Infusion1 trial

Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

Withdrawn·LLisata Therapeutics, Inc.·Phase 1/2·NCT06592664

Clinical Trial1 trial

Investigator-initiated Clinical Trial of MIKE-1

Recruiting·NNagoya University·Phase 1/2·NCT05064618·55 enrolled

Lymphoma1 trial

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169790

Regulatory

FDA Approval Timeline[5]

Jan 7, 2005

ABRAXANE

NDA NDA021660

Feb 15, 2007

ABRAXANE

NDA NDA021660

Jul 1, 2008

ABRAXANE

NDA NDA021660

Jun 26, 2009

ABRAXANE

NDA NDA021660

Dec 23, 2011

ABRAXANE

NDA NDA021660

Dec 23, 2011

ABRAXANE

NDA NDA021660

Dec 23, 2011

ABRAXANE

NDA NDA021660

Sep 28, 2012

ABRAXANE

NDA NDA021660

Sep 28, 2012

ABRAXANE

NDA NDA021660

Oct 11, 2012

ABRAXANE

NDA NDA021660

Dec 10, 2012

ABRAXANE

NDA NDA021660

Jun 7, 2013

ABRAXANE

NDA NDA021660

Sep 6, 2013

ABRAXANE

NDA NDA021660

Oct 30, 2013

ABRAXANE

NDA NDA021660

Apr 28, 2014

ABRAXANE

NDA NDA021660

Dec 11, 2014

ABRAXANE

NDA NDA021660

Jul 21, 2015

ABRAXANE

NDA NDA021660

Nov 2, 2015

ABRAXANE

NDA NDA021660

Mar 24, 2016

ABRAXANE

NDA NDA021660

Aug 16, 2018

ABRAXANE

NDA NDA021660

Dec 6, 2019

ABRAXANE

NDA NDA021660

Aug 25, 2020

ABRAXANE

NDA NDA021660

Sources

References

[1]
ClinicalTrials.gov — 633 trial records for Nab-paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Abraxane drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Nab-paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Nab-paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021660). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bristol-Myers Squibb

Abraxane

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Pancreatic Cancer51 trials

Breast Cancer34 trials

Non-Small Cell Lung Cancer11 trials

Pancreatic Adenocarcinoma11 trials

Pancreatic Ductal Adenocarcinoma9 trials

Triple-Negative Breast Cancer7 trials

Nab-paclitaxel6 trials

Chemotherapy4 trials

Squamous Cell Carcinoma3 trials

Advanced Solid Tumors3 trials

Lung Cancer2 trials

Efficacy and Safety2 trials

Gastric Cancer2 trials

Urothelial Carcinoma2 trials

Refractory Solid Tumors2 trials

Neoadjuvant Chemotherapy2 trials

Advanced Malignancies2 trials

Metastatic2 trials

Head and Neck Squamous Cell Carcinoma2 trials

Immunotherapy2 trials

First Line Therapy2 trials

Locally Advanced Head and Neck Cancer1 trial

Colorectal Cancer1 trial

Recurrent or Metastatic1 trial

Head and Neck Cancer1 trial

Radiotherapy1 trial

Patients With Advanced Solid Tumors1 trial

Urothelial Cancer1 trial

Ovarian Cancer1 trial

ESS1 trial

Desmoplastic Small Round Cell Tumor1 trial

Metastatic Melanoma1 trial

Melanoma1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Esophageal Carcinoma1 trial

Adenocarcinoma1 trial

Concurrent Chemoradiotherapy1 trial

Adult Subject1 trial

Nausea and vomiting1 trial

Nasopharyngeal Carcinoma1 trial

Recurrent Head and Neck Cancer1 trial

Bladder Cancer1 trial

Metastatic NSCLC1 trial

Non-squamous NSCLC1 trial

Locally Advanced1 trial

Locally Advanced or Metastatic NSCLC1 trial

PD-L1 Positive1 trial

Hyperbilirubinemia1 trial

Esophageal Cancer1 trial

Malignant Tumors1 trial

Merkel Cell Carcinoma1 trial

Soft Tissue Sarcoma1 trial

Locally Advanced/Metastatic Solid Tumors1 trial

Unresectable Cancer1 trial

Intrahepatic Cholangiocarcinoma1 trial

Cancer1 trial

Radiation Therapy1 trial

Infusion1 trial

Clinical Trial1 trial

Lymphoma1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News